Many providers (83%) were somewhat/very familiar with the NHLBI guidelines about HU use in SCD. Among those surveyed, the most frequent indications to start HU were: 1) history of 3 painful episodes, 2) acute c
Twenty-six percent of providers reported more than 20% of their patients/families refused HU due to: fear of cancer (51%) and other side effects (62%), don't want to take medication (49%), required laboratory monitoring (28%), and don't think it will work (17%). Not all ...
The provider mHealth intervention, Hydroxyurea Toolbox ( HU Toolbox ), addresses the clinical knowledge barriers in prescribing and monitoring hydroxyurea. The primary hypothesis is that among adolescents and adults with SCD, adherence to hydroxyurea, as measured by the proportion of days covered (...
The multiple responses of individuals with SCD demand a thorough analysis and monitoring of participants’ biomarkers, blood cell counts, and metabolites. When a patient is unresponsive, the interesting thing to explore will be whether the treatment is not very effective due to PK-related effects ...